Analysis of the PPMI dataset has shown that compared to people with sporadic forms of Parkinson’s, newly diagnosed people carrying GBA mutations are less severely impaired, and those with LRRK2 mutations appear more mildly affected.
Ambroxol was found to be safe and well tolerated in an open label trial in 18 people with Parkinson’s. It enters the brain and appears to increase levels of its chemical target GCase.
New research into the cellular clearance pathways governed by the GBA gene has shown reduced activity associated with both ageing and idiopathic Parkinson’s.
Using the largest ever genetics dataset
Insights into pathways in mitochondria and oxidative stress